News coverage about PRA Health Sciences (NASDAQ:PRAH) has been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies positive and negative news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. PRA Health Sciences earned a news impact score of 0.11 on Accern’s scale. Accern also assigned headlines about the medical research company an impact score of 46.8290163688771 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
These are some of the news headlines that may have impacted Accern’s scoring:
- PRA Health Sciences (PRAH) Upgraded to Strong-Buy at BidaskClub (americanbankingnews.com)
- PRA Health Sciences Inc (PRAH) Given Consensus Rating of “Buy” by Brokerages (americanbankingnews.com)
- How much this stock is Risky? PRA Health Sciences, Inc. (PRAH)’s Beta value is at 0.45 – Nasdaq Fortune (press release) (nasdaqfortune.com)
- PRA Health Sciences Receives CRO Leadership Award Nasdaq … – GlobeNewswire (press release) (globenewswire.com)
Shares of PRA Health Sciences stock opened at $90.77 on Monday. The company has a debt-to-equity ratio of 1.31, a current ratio of 0.90 and a quick ratio of 0.90. The firm has a market cap of $5,790.30, a PE ratio of 68.77, a price-to-earnings-growth ratio of 1.42 and a beta of 0.46. PRA Health Sciences has a 1-year low of $58.08 and a 1-year high of $95.90.
A number of equities analysts have recently issued reports on PRAH shares. BidaskClub upgraded shares of PRA Health Sciences from a “buy” rating to a “strong-buy” rating in a report on Wednesday, December 27th. Barclays began coverage on shares of PRA Health Sciences in a research report on Monday, December 11th. They issued an “overweight” rating and a $94.00 target price on the stock. Zacks Investment Research cut shares of PRA Health Sciences from a “buy” rating to a “hold” rating in a research report on Thursday, January 18th. Mizuho cut shares of PRA Health Sciences from a “buy” rating to a “neutral” rating and set a $86.00 price target on the stock. in a research report on Wednesday, January 24th. Finally, KeyCorp reiterated a “buy” rating and set a $100.00 price objective on shares of PRA Health Sciences in a research note on Wednesday, January 31st. One research analyst has rated the stock with a sell rating, one has given a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company’s stock. PRA Health Sciences has a consensus rating of “Buy” and a consensus price target of $95.67.
In other news, EVP David W. Dockhorn sold 72,850 shares of the stock in a transaction that occurred on Thursday, December 28th. The stock was sold at an average price of $90.83, for a total value of $6,616,965.50. Following the completion of the sale, the executive vice president now directly owns 72,850 shares of the company’s stock, valued at $6,616,965.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Linda Baddour sold 67,000 shares of the company’s stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $90.27, for a total value of $6,048,090.00. The disclosure for this sale can be found here. In the last three months, insiders sold 212,700 shares of company stock valued at $19,282,021. 2.10% of the stock is currently owned by company insiders.
WARNING: “PRA Health Sciences (PRAH) Earning Somewhat Favorable Press Coverage, Analysis Shows” was first posted by BBNS and is owned by of BBNS. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this piece can be read at https://baseballnewssource.com/2018/03/19/pra-health-sciences-prah-earning-somewhat-favorable-press-coverage-accern-reports/2014678.html.
About PRA Health Sciences
PRA Health Sciences, Inc is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.
Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.